|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...54555657585960616263646566» |
- |||||||||| Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
New P3 trial: Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects (clinicaltrials.gov) - May 29, 2012
P3, N=200, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||| ceftaroline fosamil / Generic mfg.
Clinical data, New P3 trial: Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia (clinicaltrials.gov) - May 23, 2012
P3, N=12, Completed, Sponsor: Albany Medical College
- Trial completion, Nontuberculous mycobacteria: NTM: PK and PD of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients (clinicaltrials.gov) - May 20, 2012
P=N/A, N=26, Completed, Sponsor: Radboud University
Recruiting --> Completed
- | Trial completion: Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida (clinicaltrials.gov) - May 20, 2012
P1, N=40, Completed, Sponsor: NovaDigm Therapeutics, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- New P3 trial: Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia (clinicaltrials.gov) - May 17, 2012
P3, N=0, Withdrawn, Sponsor: Pfizer
- | ciprofloxacin (Q3939) / Bayer, Novartis
Enrollment open: A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia (clinicaltrials.gov) - May 17, 2012
P3, N=30, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| doripenem / Generic mfg.
Trial completion: A Study of Doripenem in Infants Less Than 12 Weeks of Age (clinicaltrials.gov) - May 17, 2012
P1, N=52, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Trial completion: Evaluation of Boostrix™10 Years After Previous Booster Vaccination (clinicaltrials.gov) - May 16, 2012
P4, N=180, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- | Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
New P2 trial: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - May 16, 2012
P2, N=471, Recruiting, Sponsor: AIDS Clinical Trials Group
- Sirturo (bedaquiline) / J&J, Pharmstandard
New P3 trial: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (clinicaltrials.gov) - May 15, 2012
P3, N=0, Withdrawn, Sponsor: Janssen Infectious Diseases BVBA
- ||||| Enrollment change: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years (clinicaltrials.gov) - May 14, 2012
P3b, N=1400, Active, not recruiting, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=1150 --> 1400
- New P1 trial: Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - May 14, 2012
P1, N=60, Active, not recruiting, Sponsor: Infectious Disease Research Institute
- Trial completion: the StaphMRG Study: Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients (clinicaltrials.gov) - May 13, 2012
P=N/A, N=571, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=1150 --> 1400 Recruiting --> Completed
- Clinical: Home-sampling in Partner Notification of Chlamydia (clinicaltrials.gov) - May 9, 2012
P=N/A, N=633, Completed, Sponsor: Ostergotland County Council, Sweden
- ||||||| Trial completion: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life (clinicaltrials.gov) - May 9, 2012
P3, N=750, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Shigella Sonnei OSPC-rDT Conjugate Vaccine (clinicaltrials.gov) - May 9, 2012
P1, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Shigella Sonnei OSPC-rDT Conjugate Vaccine (clinicaltrials.gov) - May 9, 2012
P1, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Withdrawn N=60 --> 0
- New P2 trial: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (clinicaltrials.gov) - May 7, 2012
P2, N=40, Recruiting, Sponsor: Michael Boyle
- Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
New P4 trial: Understanding the Immune Response to Two Different Meningitis Vaccines (clinicaltrials.gov) - May 6, 2012
P4, N=15, Active, not recruiting, Sponsor: University of Oxford
- |||| rifampicin / Generic mfg.
Enrollment open: TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment (clinicaltrials.gov) - May 6, 2012
P2, N=850, Recruiting, Sponsor: Centers for Disease Control and Prevention
N=60 --> 0 Active, not recruiting --> Recruiting
- Trial completion: Immune Response to Mycobacterium Tuberculosis Infection (clinicaltrials.gov) - May 3, 2012
P=N/A, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- exeporfinium chloride (XF-73) / Destiny Pharma
New P1 trial: Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 (clinicaltrials.gov) - May 3, 2012
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||||| moxifloxacin ophthalmic / Generic mfg., ofloxacin ophthalmic / Generic mfg.
Enrollment open: An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients (clinicaltrials.gov) - May 2, 2012
P3, N=1042, Recruiting, Sponsor: Alcon Research
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Solithera (solithromycin) / Melinta Therap, Fujifilm Holdings
New P2 trial: Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea (clinicaltrials.gov) - May 2, 2012
P2, N=60, Completed, Sponsor: Cempra Pharmaceuticals
- ||||||| Priorix (MMR vaccine) / GSK
Trial completion: Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children (clinicaltrials.gov) - May 2, 2012
P3, N=387, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Enrollment change: Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings (clinicaltrials.gov) - May 1, 2012
P2, N=270, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=180 --> 270
- rifampicin/isoniazid/ethambutol/pyrazinamide / Generic mfg.
New P2a trial: Essentiality of INH in TB Therapy (clinicaltrials.gov) - Apr 30, 2012
P2a, N=45, Not yet recruiting, Sponsor: AIDS Clinical Trials Group
- ||| rifampicin / Generic mfg.
Enrollment open: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=1634, Recruiting, Sponsor: Cepheid
N=180 --> 270 Not yet recruiting --> Recruiting
- ||||||| Trial completion: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age (clinicaltrials.gov) - Apr 29, 2012
P3, N=175, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Recruiting --> Completed
- || New P3 trial: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC (clinicaltrials.gov) - Apr 29, 2012
P3, N=500, Recruiting, Sponsor: Institute of Tropical Medicine, Belgium
- |||| Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
Trial completion: Study of Adacel® Vaccine Administered to Persons 10 Years of Age (clinicaltrials.gov) - Apr 26, 2012
P4, N=1302, Completed, Sponsor: Sanofi
Recruiting --> Completed Active, not recruiting --> Completed
- Ilaris (canakinumab) / Novartis
Trial completion: Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Apr 26, 2012
P2, N=10, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change, Diagnostic assay: A Study in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=21, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=32 --> 21
- aspirin / Generic mfg.
Clinical: Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=904, Completed, Sponsor: Chinese University of Hong Kong
- | Trial completion: Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients (clinicaltrials.gov) - Apr 24, 2012
P2, N=32, Completed, Sponsor: Foamix Ltd.
N=32 --> 21 Recruiting --> Completed
- ||| SQ-109 / Sequella
New P1 trial: Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers (clinicaltrials.gov) - Apr 24, 2012
P1, N=62, Completed, Sponsor: Sequella, Inc.
- ||||| Enrollment change: Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 (clinicaltrials.gov) - Apr 22, 2012
P2/3, N=817, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed N=1625 --> 817
- albendazole / Generic mfg., azithromycin / Generic mfg.
Adverse events: AZIVAL: Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=3000, Completed, Sponsor: Centre d'Appui à la lutte contre la Maladie
- ||||||| Trial completion: Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 (clinicaltrials.gov) - Apr 22, 2012
P2/3, N=817, Completed, Sponsor: Novartis Vaccines
N=1625 --> 817 Recruiting --> Completed
- mupirocin / Generic mfg.
Trial completion: SuDS: Staphylococcus Aureus Decolonization Study (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=183, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed
- | Shanchol (oral cholera vaccine) / Sanofi
New P4 trial: Evaluation of a Boosting Regimen With Oral Cholera Vaccine (clinicaltrials.gov) - Apr 16, 2012
P4, N=426, Completed, Sponsor: Sachin Desai
- | Trial completion: Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children (clinicaltrials.gov) - Apr 16, 2012
P3, N=2394, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | sodium phenylbutyrate / Generic mfg.
New P2 trial: Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB) (clinicaltrials.gov) - Apr 16, 2012
P2, N=288, Active, not recruiting, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
- Clinical: Hospital Wide Roll-Out of Antimicrobial Stewardship (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=20000, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial: PCV13-Bobo: Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso (clinicaltrials.gov) - Apr 12, 2012
P4, N=765, Active, not recruiting, Sponsor: Agence de Médecine Préventive, France
- linezolid oral / Generic mfg.
Enrollment closed: Linezolid to Treat Extensively-Drug Resistant Tuberculosis (clinicaltrials.gov) - Apr 12, 2012
P2, N=41, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial completion: Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (clinicaltrials.gov) - Apr 12, 2012
P3, N=370, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Clinical: Procalcitonin in Cirrhotic Patients at High Risk for Sepsis (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=75, Completed, Sponsor: Prof. Facchinetti Fabio
- MenAfriVac (meningococcal A conjugate vaccine) / Serum Institute of India
Trial initiation date: A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger (clinicaltrials.gov) - Apr 11, 2012
P=N/A, N=0, Withdrawn, Sponsor: London School of Hygiene and Tropical Medicine
Active, not recruiting --> Completed Initiation date: Feb 2011 --> Feb 2012
- ||| Altabax (retapamulin) / GSK, Almirall
Enrollment change: Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. (clinicaltrials.gov) - Apr 11, 2012
P4, N=60, Completed, Sponsor: GlaxoSmithKline
Initiation date: Feb 2011 --> Feb 2012 N=87 --> 60